Share
739 Posts.
lightbulb Created with Sketch. 73
clock Created with Sketch. 22/12/23
10:34
Share
Originally posted by jellyroll:
↑
They are certainly not making it easy to keep holding. The lack of new news is making it easy to question certain assumptions. In particular why was Cogstate not used for the market surveillance for Leqembi and where will Cognigram fit in to the clinical diagnostic pathway for AD. I think there are good answers for both but they are reasonable questions. In particular as there is currently no reimbursement in the US, for digital cognitive tests in AD, how much of the diagnostic purse will Cognigram be able to capture in the near term.
Expand
Has management ever hinted they are or will be involved with ozempic alzheimer's studies?
(20min delay)